Eosinophil and Anticoagulation in COVID-19 Patients

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bursa Yüksek İhtisas Hastanesi

Yıldırım, 16310, Turkey (Türkiye)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
agreed to participate in the study were included

Exclusion criteria

Patients with previous coagulopathy,
continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Treatment and study plan

LMWH

Drug

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Primary outcomes

subprophylactic anticogulation level

Time frame: 14 days

<0.2IU/ml

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Bursa Postgraduate Hospital

Other

Registry information

Official study title

Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Aug 11, 2020
Registry last updated: Aug 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed